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Abstract
Background: Arsenic, a major pollutant of water as well as soil, is a known endocrine disruptor, and shows adverse 
effects on the female reproductive physiology. However, the exact molecular events leading to reproductive 
dysfunctions as a result of arsenic exposure are yet to be ascertained. This report evaluates the effect and mode of 
action of chronic oral arsenic exposure on the uterine physiology of mature female albino rats.
Methods: The effect of chronic oral exposure to arsenic at the dose of 4 microg/ml for 28 days was evaluated on adult 
female albino rats. Hematoxylin-eosin double staining method evaluated the changes in the histological architecture 
of the uterus. Circulating levels of gonadotropins and estradiol were assayed by enzyme-linked immunosorbent assay. 
Expression of the estrogen receptor and estrogen-induced genes was studied at the mRNA level by RT-PCR and at the 
protein level by immunohistochemistry and western blot analysis.
Results: Sodium arsenite treatment decreased circulating levels of estradiol in a dose and time-dependent manner, 
along with decrease in the levels of both LH and FSH. Histological evaluation revealed degeneration of luminal 
epithelial cells and endometrial glands in response to arsenic treatment, along with reduction in thickness of the 
longitudinal muscle layer. Concomitantly, downregulation of estrogen receptor (ER alpha), the estrogen-responsive 
gene - vascular endothelial growth factor (VEGF), and G1 cell cycle proteins, cyclin D1 and CDK4, was also observed.
Conclusion: Together, the results indicate that arsenic disrupted the circulating levels of gonadotropins and estradiol, 
led to degeneration of luminal epithelial, stromal and myometrial cells of the rat uterus and downregulated the 
downstream components of the estrogen signaling pathway. Since development and functional maintenance of the 
uterus is under the influence of estradiol, arsenic-induced structural degeneration may be attributed to the reduction 
in circulating estradiol levels. Downregulation of the estrogen receptor and estrogen-responsive genes in response to 
arsenic indicates a mechanism of suppression of female reproductive functions by an environmental toxicant that is 
contra-mechanistic to that of estrogen.
Background
Arsenic is a naturally occurring metalloid with potent
toxic and mutagenic effects [1]. It is present ubiquitously
in the environment and is released from both natural and
man-made sources [2]. Arsenic in drinking water is one
of the topmost environmental threats worldwide, based
on the potential exposure of people to arsenic and the
numerous diseases with which it has been associated [3-
6]. In Southeast Asian countries like India, Bangladesh
and Taiwan, millions of people are threatened by arsenic
poisoning, leading to several diseases and disorders, and
even death [7]. The problem of arsenic poisoning is not
only restricted to developing countries but developed
nations like USA, Germany, China, Japan and Australia
are also plagued by problems of arsenic contamination
[8,9]. Interestingly, inorganic arsenic is found to be more
potent than the organic form and trivalent compounds
are found to be more toxic than pentavalent ones [10].
Chronic intake of arsenic is strongly associated with an
increased risk of skin, lung, liver and other cancers, type 2
diabetes, cardiovascular diseases, neurological and cogni-
tive defects, and reproductive and developmental prob-
lems [11-16]. According to World Health Organization,
the permissible limit of arsenic in drinking water is 0.01
mg/l, which is equivalent to 10 ppb [9,15,17,18]. Recently,
however, it has been reported that there is an increased
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risk of arsenic toxicity, even at the low and permissible
dose of 10 ppb [9,15-17]. However, a large population all
over the world is exposed to far higher levels of arsenic
[19-23]. In certain areas in the Indian subcontinent, the
maximum arsenic concentration in ground water was
found to be around 3700 ppb [24] to 4700 ppb [18], lead-
ing to several physiological damages to human beings.
Although arsenic is not a direct acting xenotoxin or
mutagen, it may increase DNA damage or mutations
indirectly by altering DNA repair, thus acting as a co-car-
cinogen or promoter of tumor growth [25].
Till date, there is very little information regarding the
mechanism of arsenic action on the ovarian steroidogenic
function and the female reproductive axis, particularly in
wide areas of India and other countries, where the levels
occurring in drinking water exceed the admissible limits
of 10 ppb [20-22,24]. It is, however, known that women
who are exposed to this level of arsenic often suffer from
spontaneous abortion and stillbirth [26], and maternal
exposure to arsenic also affects the health of newborn
and promotes carcinoma incidences in them [27-29].
Although it has been hypothesized that the reproductive
hazards may be due to disruption of the steroid hormone
signaling pathway [30,31], the actual target of arsenic is
probably a part of the mechanism which is used to regu-
late gene expression and not just the receptor itself [31].
The estrogen receptor (ER) is the most divergent of all
steroid hormone receptors and may undergo divergent
co-regulatory interactions and unique activation/de-acti-
vation steps. Previous studies have suggested that arsenic
can interfere with ER functioning, although the exact
mechanism remains to be ascertained [31]. Since arsenic
acts as a potent environmental estrogen [32], it was expli-
cable to study the arsenic-stimulated estrogen receptor
signaling pathway, expression of estrogen responsive
genes such as VEGF, and G1 cell cycle regulatory proteins
CDK4 and cyclin D1, since these molecules are known to
be primary responsive factors to estrogen administration
in the rat uterine endometrium [33-35]. Thus, the objec-
tive of this study was to elucidate the role of arsenic as an
endocrine disruptor and determine the molecular mech-
anism underlying arsenic action in the rat uterus.
Methods
Animals
Female Sprague-Dawley rats, aged 15-16 weeks and
weighing 100-120 g, were collected from the breeding
colony and maintained under controlled conditions (25 ±
2°C temp, 50 ± 15% RH and normal photoperiod 12 h
dark and 12 h light) through out the experiment. The ani-
mals were given sterile food pellets and water ad libitum
and allowed to acclimatize to the laboratory environment
for 5 days prior to the commencement of the experi-
ments. The Principles of Laboratory Animal Care (NIH
Publication No 85-23, revised in 1985) as well as specific
Indian Laws of Animal Protection (ILAP) were followed
through out the experimental schedule.
Drug treatments, selection of optimum dose and time and 
study of estrous cycle
Sodium arsenite (E-Merck, Germany) was used for study.
All other chemicals were procured from Sigma Aldrich
(USA). The rats were divided randomly into different
groups, each containing 5 animals. Group I (control
group) animals were fed 10-12 ml pure distilled water/
animal/day, while other groups were fed the same volume
of water containing sodium arsenite at different concen-
trations (0.4 μg/ml, 4 μg/ml, 40 μg/ml and 80 μg/ml) [27-
29,36-38] and maintained for different time periods (7
days, 14 days, 28 days and 56 days) in order to determine
the optimum dose and time of arsenic action. The opti-
mum time and dose of arsenic action, as determined by
circulating estradiol concentrations, were selected for all
s u b s e q u e n t  e x p e r i m e n t s .  T h e  d o s e  o f  a r s e n i c  t h u s
selected conforms to environmentally relevant concen-
trations. Vaginal smears were collected every morning
from all of the animals before fresh treatment of arsenic.
The smears were double stained with eosin-hematoxylin
and examined microscopically.
Tissue and blood collection
Animals were anesthetized by intraperitoneal injection of
sodium barbital. Uteri were quickly removed from the
experimental animals and washed in 0.9% (w/v) cold nor-
mal saline, pat dried and weighed in an electrical
monopan balance (Lutron GM-300 P). Small representa-
tive tissue slices were processed for histological and
immunohistochemical studies, RNA isolation and pro-
tein purification. Blood was collected from the heart and
serum was isolated for ELISA.
Assay of serum estradiol, LH and FSH
ELISA (DRG International ELISA Kit) was performed for
estimating the circulating levels of estradiol, LH and FSH.
For assay of serum estradiol, 25 μl each of standard, con-
trol and treated serum samples were added to respective
wells coated with anti-estradiol antibody and incubated
with 200 μl of enzyme conjugate for 2 hours at room tem-
perature. Subsequently, 100 μl of substrate was added and
incubated for 15 minutes at room temperature. Reactions
were stopped using 50 μl of stop solution and the O.D.
was measured at 450 nm. Each sample was run in tripli-
cate [39]. For assay of serum FSH and LH, 25 μl of stan-
dard, control or treated serum samples were added to
respective wells coated with anti-FSH and anti-LH anti-
bodies and incubated with 100 μl of enzyme conjugate for
30 minutes at room temperature. Wells were washed with
aqua dest and 100 μl of substrate was added to each well.
After incubation for 10 minutes at room temperature,Chatterjee and Chatterji Reproductive Biology and Endocrinology 2010, 8:80
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reactions were stopped using 50 μl of stop solution and
the O.D. measured at 450 nm [38,39]. The intra-assay and
inter-assay variations were found to be less than 9% and
10%, respectively. Limit of detection for estradiol was 3.6
pg/ml, for LH was 0.45 mIU/ml and for FSH was 0.28
mIU/ml.
Histology and morphometric analysis
Uterine slices (selected randomly from the proximal,
middle and distal regions of the uterus) from control and
treated animals were fixed in bouins fluid. Graded dehy-
dration of the tissue was done by 70 to 100% alcohol in
subsequent steps and xylene was used as the clearing
agent. For histological studies, 5 μ paraffin sections were
stained by standard hematoxylin-eosin double staining
procedure and observed under a microscope [31]. The
stained sections were subjected to morphometric analysis
using the eye piece scale (occulometer) and the stage
micrometer. The stage and the eye piece scales were
adjusted until there was a parallel point between the two
scales. The number of the eye piece divisions and its cor-
responding stage measurements was noted. The occu-
lometer fixed into the microscope was then focused
through stained sections of the tissue to allow for mea-
surement of the luminal diameter, height of luminal epi-
thelial cells, size of endometrial glands and longitudinal
muscle layer [40].
Immunohistochemistry
Immunohistochemistry was performed according to a
previously established protocol [26]. Briefly, sections
were deparaffinized, hydrated, boiled in 0.1 M sodium
citrate buffer (pH 6.0) for 10 minutes and treated with 3%
(v/v) H2O2 in PBS (30 min) to block endogenous peroxi-
dase activity. Non-specific staining was blocked by incu-
bating the sections with bovine serum at room
temperature. Sections were subsequently incubated with
rabbit anti-ER IgG (sc-542, Santa Cruz Biotech, CA,
1:500) for 18 hours at 4°C and then with goat anti-rabbit
HRP-conjugated secondary antibody (1:1000) for 1 hour
at room temperature. Peroxidase was visualized using
3,3'-diaminobenzidine. The sections were counterstained
with hematoxylin. Slides that served as negative controls
were not incubated with the primary antibody [27].
RNA extraction and semi-quantitative RT-PCR
Uterine tissues were collected from the arsenic-treated
and untreated rats. 100 mg of tissue samples were frozen
quickly in liquid nitrogen and total RNA was isolated
using TRI reagent (SIGMA), dissolved in DEPC water
and quantified by UV spectrophotometry. The RNA sam-
ples were subjected to DNase treatment prior to RT-PCR.
Reverse transcription reaction was performed at 42°C
with 5 μg of RNA in 5× reaction buffer (Fermentas, USA)
containing 100 pmol random hexamer primer, 10 mM
dNTP mixture (Fermentas, USA), 20 units of RNase
inhibitor (Bioline, USA) and 200 units of RevertAid™ M-
MuLV Reverse Transcriptase (Fermentas, USA). PCR was
initiated using 2.5 μg cDNA, 10 mM dNTPs and 1 unit of
Taq DNA Polymerase (Vivantis, USA). PCR amplifica-
tions were performed using the primers listed in Table
1[41-45]. PCR was carried out for 40 cycles using an
annealing temperature of 58°C for ERα and 55°C for
VEGF, CDK4 and cyclin D1. Samples were fractioned by
2% agarose gel electrophoresis and quantified using a
BioRad Gel Documentation System.
Western blot analysis
Tissue samples were lysed in ice-cold RIPA Buffer (150
mM NaCl, 50 mm Tris, 0.1% Triton X-100 and 0.1% SDS
containing protease inhibitors [4-(-2-aminoethyl benze-
nesulphonyl fluoride), EDTA, leupeptin, aprotinin and
bestatin, SIGMA]. The concentration of total protein was
determined by Bradford assay and equal amount of pro-
teins (30 μg) were fractioned by 8% SDS-PAGE. Proteins
were electrically transferred to PVDF membranes and
blocked for 2 hours at room temperature with 5% non-fat
dry milk. Blots were subsequently incubated with ERα,
VEGF and CDK4 antibodies raised in rabbit and cyclin
D1 antibody raised in mouse (1:1000), for 18 hours at 4°C.
Anti-β tubulin was used as a loading control. Blots were
subsequently incubated with HRP-conjugated goat anti-
rabbit and goat anti-mouse IgG secondary antibodies
(1:2000), respectively, for 1 hour at 25°C. Immunoreactive
proteins were detected by staining the membranes with
3,3'-diaminobenzidine in 50 mM Tris (pH-7) containing
0.2% H2O2 [46] and bands were quantified by a BioRad
Gel Documentation System.
Table 1: Sequences of the oligonucleotides used for semi-quantitative RT-PCR
Gene Forward primer Reverse primer Ref.
ER α GGAGACATGAGAGCTGCCAAC CCAGCAGCATGTCGAAGATC [41]
VEGF GATCAAGTTCATGGACGTCT GATCAAGTTCATGGACGTCT [43]
Cyclin D1 CTGGCCATGAACTACCTGGA GTCACACTTGATCACTCTGG [45]
GAPDH GACATCAAGGTGGTGAAGCAG CACCCTGTTGCTGTAGCCATATTC [42]
CDK4 TGGTGTCGGTGCCTATGGGA GGTAGCTGTAGATTCTGGCT [44]Chatterjee and Chatterji Reproductive Biology and Endocrinology 2010, 8:80
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Statistical analysis
Results of the experiments performed in triplicates were
expressed as mean and standard error of mean of differ-
ent groups, using a statistical software package (Graph-
pad). The differences between the mean values were
evaluated by one-way ANOVA followed by multiple Stu-
dents' t-tests. P-values less than 0.05 were considered sta-
tistically significant [47,48]. Densitometric analysis of the
RT-PCR and western blot results were carried out using
NIH Scion Image analysis to assess the fold-change in
arsenic-treated rats as compared to the control animals.
Results
Effect of arsenic on food consumption, body weight and 
estrous cycle
It was observed that during the entire duration of the
experiment, water intake and food consumption of the
control and treated rats remained unchanged. In addi-
tion, the body weights of the treated animals were not sig-
nificantly different from that of the control ones.
However, after 28 days of arsenic treatment, a significant
decrease in the wet weight of uterus was observed in
comparison to the control group (Table 2). In addition, in
the control group, regular estrous cycles of 4-5 days were
noted whereas, in the arsenite-treated group, a constant
diestrous phase was observed after 22 ± 2 days of arsenic
treatment.
Dose and time-dependent effect of arsenic on serum 
estradiol levels
In order to determine the effect of arsenic on serum
estradiol levels in female Sprague-Dawley rats, the opti-
mum dose responsible for the changes and the minimum
time required to initiate maximum changes were resolved
by ELISA of serum estradiol. Rats were treated with dif-
ferent doses of sodium arsenite and monitored at the end
of 28 days. As depicted in Figure 1a, the serum estradiol
levels reduced at a dose of 0.4 μg/ml and decreased by 4-
fold in rats fed with arsenic-containing water at a dose of
4 μg/ml, as compared to control rats (p < 0.05). The level
did not decrease further when the rats were fed arsenic-
containing water at the dose of 40 μg/ml and 80 μg/ml.
The minimum time required for maximum effect of arse-
nic was resolved to be 28 days, beyond which continuous
treatment did not affect the serum estradiol levels up to a
period of 56 days (Figure 1b). Hence, all subsequent
experiments were performed with the optimum effective
dose and time of 4 μg/ml (equivalent to 4 ppm) and 28
days, respectively.
Effect of arsenic on serum concentration of LH and FSH
LH and FSH are gonadotropins which are upstream com-
ponents of estradiol signaling, and are required for the
Table 2: Body weight and uterine wet weight in response to 
4 μg/ml arsenic treatment for 28 days in adult female rats
Treatment Body weight (in gm) Uterine wet 
weight (in mg)
Control 132 ± 1.67 146 ± 2.31
4 μg/ml NaAsO2 131.6 ± 1.32 104.3 ± 1.94**
Individual weights of control and arsenic-treated rats were 
attained at the end of the experimental schedule. Each value 
represents mean ± SE, n = 5. (ANOVA followed by multiple 
Students' t-tests, ** p < 0.01, as compared with respective control).
Figure 1 Serum estradiol levels of untreated and arsenic treated 
female Sprague Dawley rats. Rats were exposed to different doses of 
sodium meta-arsenite for different time periods, as mentioned in the 
Methods section. (a) Arsenic has a dose-dependent inhibitory effect on 
circulating estradiol levels. The dose at which maximum reduction is 
observed is 4 μg/ml, beyond which the level does not change signifi-
cantly. Each value represented as mean ± SE, n = 3, p < 0.05. (b) The 
minimum time period required to initiate the maximum decrease in 
estradiol levels is 28 days. No further reduction is observed even when 
rats were exposed to arsenic for 56 days. Each value represented as 
mean ± SE, n = 3, p < 0.05.
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development and quantitative maintenance of normal
reproductive cycle in pubertal rats. It was observed that
chronic exposure of rats to 4 μg/ml sodium arsenite for
28 days significantly decreased the serum LH and FSH
concentrations (Figure 2), as detected by ELISA. Synthe-
sis and secretion of estradiol is under the control of these
gonadotropins, hence rendering them important compo-
nents of sex steroid regulation. Thus, the reduction of LH
and FSH may therefore be responsible for the consequent
reduction in estradiol levels, as seen above.
Arsenic-induced histological changes of the uterus
Histological analysis of 4 μg/ml arsenic-treated rats
showed significant alterations in the uterine morphology
as compared to the untreated rats. Occulometric studies
r e v e a l e d  r a t s  t h a t  w e r e  e x p o s e d  t o  a r s e n i c  s h o w e d  a
decrease in (i) the size and invaginations of the uterine
luminal diameter, (ii) height of luminal epithelial cells,
(iii) number and organization of endometrial glands, and
(iv) the width of the myometrium (Table 3). The compact,
tall, columnar epithelial cells lining the highly invaginated
lumen of the untreated uterus (Figure 3a) were well
defined as compared to the treated uterus (Figure 3b),
with rounded nuclei located on a prominent basement
membrane (Figure 3c). However, the height and organiza-
tion of the epithelial cells were affected with arsenic treat-
ment and revealed distortion of the cells with irregular-
shaped nuclei, along with disappearance of a distinct
basement membrane (Figure 3d). Additionally, the num-
ber and size of endometrial glands in the endometrial
stroma were well defined in the control uterus (Figure 3e)
and were significantly reduced in the treated animals
(Figure 3f). Reduction in the thickness of the longitudinal
muscles comprising the myometrium, as compared to the
untreated uterus (Figure 3g), was also observed in the
uterus of rats exposed to arsenic (Figure 3h).
Effect of arsenic on estrogen receptor expression
Immunohistochemical localization of estrogen receptors
were detected by staining for the ERα proteins in the uteri
of arsenic treated and untreated rats. Uterus from
untreated rats showed presence of ERα (Figure 4a)
whereas rats exposed to arsenic showed significant
downregulation of ERα in the uterine endometrium (Fig-
ure 4b). Similar results were observed in the muscle layer
of the control (Figure 4c) and the arsenic-treated uterus
(Figure 4d). In order to further validate the effect of arse-
nic on the expression of estrogen receptors in the rat
uterus, the expression was monitored both at the RNA
transcript levels and at the protein levels. Semi-quantita-
tive RT-PCR confirmed that the level of ERα was down-
regulated as a result of arsenic treatment as compared to
the control uterus (Figure 5a). Western blot analyses fur-
ther confirmed that concentration of the estrogen recep-
tor protein declined by almost 2-fold as a result of
exposure to arsenic (Figure 5b).
Effect of arsenic on vascular endothelial growth factor
Since arsenic is a potent environmental estrogen and
responsible for downregulation of the estrogen receptor,
we investigated the effects of arsenic on the estrogen sig-
naling pathway. Concomitantly, we selected vascular
endothelial growth factor (VEGF) as the estrogen-
responsive gene, since it is known to respond primarily to
estrogen administration in the uterine epithelium and
stroma. The expression of VEGF was thus evaluated at
the transcriptional and translational levels. Semi-quanti-
tative RT-PCR revealed a 2-fold reduction of VEGF tran-
scripts and protein in the arsenic-treated rat uterus
(Figure 6), indicating that arsenic not only down regulates
the estrogen receptor, but also disrupts the downstream
gene expression in the rat uterus.
Effect of arsenic on the cell cycle regulatory proteins
It is well established that decreased levels of estrogen can
affect the expression of the cell cycle regulators, espe-
cially those that are involved in the G1-S transition,
chiefly cyclin D1 and CDK4. Concomitantly, we investi-
gated if arsenic, which decreased the serum estradiol lev-
els and estrogen receptor expression in female rats, would
additionally alter the expression of cyclin D1 and CDK4.
The results indicated significant reduction in cyclin D1
and CDK4 mRNA levels in uteri of rats exposed to arse-
nic, as compared to unexposed rats (Figure 7a). Concom-
itant downregulation in the expression of cyclin D1 and
CDK4 proteins was also observed in uteri of rats exposed
to arsenic treatment (Figure 7b).
Figure 2 Serum gonadotropin levels of untreated and arsenic-
treated female rats. Sprague-Dawley rats were treated with 4 μg/ml 
sodium meta-arsenite for 28 days, as described in the Methods section. 
The results indicate that arsenic has an inhibitory effect on serum levels 
of both LH and FSH (white bars), as compared to the control animals 
(black bars). Each value represented as mean ± SE, n = 3, p < 0.05.
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Discussion
In this study we report the effects of inorganic arsenic on
the estrogen signaling pathway in rats, along with con-
comitant alterations of the uterine morphology and pro-
liferation, to unravel the putative mechanisms behind
reproductive failures associated with arsenic exposure.
Rats were chronically (28 days) exposed to arsenite (4 μg/
ml) in drinking water in order to establish a correlation
between uterine pathology, serum estradiol and gonado-
tropin concentrations, and alterations in expression of
the estrogen receptor and downstream components,
involved with uterine tissue architecture and function,
following arsenic treatment. It is evident from the results
that arsenic exposure diminishes the circulating levels of
both gonadotropins and estradiol. This is further sup-
ported by the fact that ovarian steroidogenesis involves
enzymes regulated by the gonadotropins FSH and LH,
both of which have been reported to be inhibited follow-
ing exposure to arsenic [49]. Consequently, low serum
levels of FSH and LH in arsenic-treated rats lead to
reduction in estradiol production and thus secretion into
circulation. Some reports have postulated that the
decrease in gonadotropin levels may be due to an
increase in plasma glucocorticoids in arsenic-treated rats,
since increase in ACTH levels is known to suppress
gonadotropin secretion [38].
The finding that arsenic exposure did not affect the
total body weight during the exposure period, but
decreased the uterine wet weight by almost 30% may be
attributed to the fact that the effect of arsenic is very spe-
cific to the uterus in the tested time period. This is fur-
ther supported by the fact that estradiol regulates uterine
weight, and thus, low levels of estradiol lead to the spe-
cific reduction of uterine wet weight in the exposed ani-
mals. In addition, constant diestrus in arsenic-treated rats
after 20 ± 2 days may also be due to low serum levels of
estradiol [50-52].
In addition to altering the uterine wet weight, arsenic
also leads to tissue degeneration in the uterus. The
degenerative changes may be attributed to adverse effects
caused by decreased serum estradiol levels, since uterine
growth is primarily dependant on estradiol. The insuffi-
cient concentration of estradiol failed to maintain the
normal uterine architecture and led to degeneration of
the luminal epithelial cells and endometrial glands. Arse-
nic is known to generate reactive oxygen species and
leads to oxidative damage to several components of the
cell, including denaturation of proteins critical to cell
functions [53-58]. Thus, degeneration of the uterine
endometrial components may be associated not only with
downregulated serum estradiol levels but also with
increased production of reactive oxygen species following
exposure to arsenic [56].
Arsenic is known to act as a potent environmental
estrogen [32]. Subsequently, it was hypothesized that
arsenic may mimic an estrogenic mechanism to induce
lesions in the rat uterus, disrupt the estrogen signaling
pathway and consequently lead to reproductive failures.
A c c o r d i n gl y ,  t h e  e ff ect  o f  a r se n i c  o n  t h e  e x p r e s s i o n  o f
estrogen receptor, the estrogen responsive gene VEGF,
and cell cycle regulatory proteins like CDK4 and cyclin
D1 was investigated in the rat uterus. It is known that the
estrogen receptor is a hormone-activated transcription
factor which mediates the biological effects of estrogen in
the target tissue by stimulating the expression of estro-
gen-regulated genes. The sensitivity of a given tissue to
estrogen thus varies with the level of estrogen receptors
present in it [59]. Our studies have revealed that arsenic
treatment significantly downregulated the expression of
ERα and its downstream element VEGF in the uterus,
indicating that arsenic either suppresses the bonafide
action of estradiol on the uterus by decreasing the expres-
sion of specific receptors, at both the mRNA transcript
and protein levels, or acts via a parallel mechanism in the
rat uterus that eventually disrupts the estrogen signaling
pathway and the G1 cell cycle proteins responsible for cell
proliferation. Estradiol-regulated VEGF is chiefly respon-
sible for modulating in vivo angiogenesis in the uterus,
and its downregulation by arsenic may be a primary cause
for spontaneous abortions, still-births and other repro-
ductive failures. The D-type cyclins are known to be rate-
limiting for the progression through the G1 phase of the
Table 3: Luminal diameter, height of luminal epithelial cells, diameter of endometrial glands and width of longitudinal 
muscles in different experimental groups of adult female rats
Treatment Luminal diameter (μm)# Height of luminal epithelial
cells (μm)§
Diameter of endometrial
glands (μm)§
Width of longitudinal muscle
layer (μm)§
Control 45.88 ± 1.87 18.44 ± 0.19 58.95 ± 3.04 75.89 ± 0.68
4 μg/ml NaAsO2 10.72 ± 0.51** 5.7 ± .04*** 16.61 ± 0.44** 37.69 ± 1.6**
Histological analysis was carried out for each control and arsenic-treated rat, and the uterine parameters were measured by occulometry. 
Each value represents mean ± SE, n = 5. (ANOVA followed by multiple Students' t-tests, ** p < 0.01, *** p < 0.001, as compared with respective 
controls). # Magnification: 10×; § magnification: 40×.Chatterjee and Chatterji Reproductive Biology and Endocrinology 2010, 8:80
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cell cycle [60]. In fact, a strong correlation between the
expression of increased levels of cyclin D1 mRNA and ER
over-expression has been reported [61]. In addition,
estrogens are known to increase cell proliferation by
recruiting resting cells into the cell cycle, reducing the
length of G1 phase and promoting entry of cells to the S
phase [62]. Arsenic, on the other hand, decreased the
expression of uterine estrogen receptors, and conse-
quently suppressed cell cycle progression and reduced
the proliferation-promoting effects of estradiol in the rat
uterus.
Conclusions
It may thus be concluded that sodium arsenite is a non-
steroidal environmental estrogen that is responsible for
reducing the serum levels of gonadotropins and estradiol,
which in turn lead to uterine tissue degeneration and dis-
ruption of the estrogen signaling pathway. The effects of
arsenic on the uterus may occur by reducing the expres-
sion of estrogen receptors and estrogen responsive genes,
and/or by generating reactive oxygen species that lead to
oxidative damage of the proteins involved in the estrogen
signaling pathway, that regulate the uterine structure and
function. Interestingly, liver toxicity assays carried out in
our laboratory did not indicate significant differences in
the SGPT or SGOT levels in the experimental animals as
compared to the control ones (data not shown). Hence, it
may be imperative to state that level of arsenic which
failed to reduce general body weight of the rats or even
affect the liver toxicity enzymes, were capable of bringing
about such severe detrimental changes in the uterine
physiology and steroid signaling pathway. Finally, our
study demonstrates that arsenic at low but chronic doses,
relevant to the exposure level in different parts of the
world, is a major endocrine disruptor and thus, may be
Figure 3 Alterations in tissue architecture of arsenic-treated rat 
uterus. Rats were treated with or without 4 μg/ml arsenic for 28 days. 
3a, 3c, 3e and 3g: control sections; 3b, 3d, 3f and 3h: arsenic-treated 
sections. Uterine sections were subjected to double staining with he-
matoxylin and eosin and examined under the microscope. (3a, 3b) A 
significant decrease in width and invaginations of the arsenic-treated 
uterine lumen was observed in the treated sections (10× magnifica-
tion) as compared to untreated one. (3c, 3d) Reduction in the height of 
luminal epithelial cells (as measured by occulometry) in the arsenic-
treated sections was observed as compared to untreated one (40×). In 
addition, degeneration of the layer was also noted in the treated uter-
us. (3e, 3f) Arsenic treatment resulted in a significant reduction in the 
size of endometrial glands, with disappearance of the lumen and dis-
organization of the epithelial cells lining the glands. (3g, 3h) As com-
pared to the control uterus, significant reduction in size and 
organization of the longitudinal muscle layer was observed in the arse-
nic-treated uterine sections.
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
Figure 4 Immunohistochemical localization of estrogen receptor 
in the rat uterine sections. Rats were treated with arsenic for 28 days 
and tissues were stained for the presence of the estrogen receptor. Ar-
senic significantly downregulated the estrogen receptors in the endo-
metrial stroma (4b) as compared to the untreated uterus (4a). In 
addition, the expression of estrogen receptors was also decreased in 
the longitudinal muscle layer (4d) in contrast to the expression in the 
muscle layer of the control uterus (4c).
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responsible for the different reproductive failures seen in
women exposed to such levels of arsenic.
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Figure 5 Effect of arsenic on estrogen receptor expression at the 
mRNA transcript and protein levels. Downregulation of the estro-
gen receptor in the arsenic-treated uterus was observed both at the 
mRNA transcript levels, as determined by RT-PCR (a), and at the protein 
levels, as determined by western blot analysis (b). The data shown is a 
representative of the experiments carried out in triplicate.
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Figure 6 Arsenic downregulated VEGF expression in the rat uter-
us. Expression of VEGF, an estrogen-responsive gene, was observed to 
be downregulated both at the transcriptional (a) and translational lev-
els (b), as determined by semi-quantitative RT-PCR and western blot 
analysis, respectively, in the uterus of arsenic-treated rats. The data 
shown is a representative of three independent experiments.
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Figure 7 Regulation of G1 cell cycle proteins by arsenic in rats. Fe-
male rats were treated with arsenic at a dose of 4 μg/ml for 28 days. Cy-
clin D1 and CDK4 expressions were analyzed both at the mRNA levels 
(a) and protein levels (b), using GAPDH and β-tubulin as loading con-
trols, respectively. It was observed that arsenic downregulated both 
cyclin D1 and CDK4 (white bars) in the uterus of Sprague-Dawley rats, 
as compared to the control animals (black bars). The data shown is a 
representative of the experiments carried out in triplicate.
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